Group items matching

in title, tags, annotations or url

Effects of dietary flaxseed on intestinal tumorigenesis in Apc(Min) mouse. Bommareddy A, Zhang X, Schrader D, Kaushik RS, Zeman D, Matthees DP, Dwivedi C. Nutr Cancer. 2009;61(2):276-83. PMID: 19235044 DOI: 10.1080/01635580802419764

Effects of perioperative cimetidine administration on peripheral blood lymphocytes and tumor infiltrating lymphocytes in patients with gastrointestinal cancer: results of a randomized controlled clinical trial. Li Y, Yang GL, Yuan HY, Bai DJ, Wang K, Lin CR, Hu MB, Feng MH. Hepatogastroenterology. 2005 Mar-Apr;52(62):504-8. PMID: 15816467

Effects of eicosapentaenoic and docosahexaenoic n-3 fatty acids from fish oil and preferential Cox-2 inhibition on systemic syndromes in patients with advanced lung cancer. Cerchietti LC, Navigante AH, Castro MA. Nutr Cancer. 2007;59(1):14-20. PMID: 17927497

The effect of dietary omega-3 polyunsaturated fatty acids on T-lymphocyte subsets of patients with solid tumors. Gogos CA, Ginopoulos P, Zoumbos NC, Apostolidou E, Kalfarentzos F. Cancer Detect Prev. 1995;19(5):415-7. PMID: 7585727

Effect of moderate exercise training on T-helper cell subpopulations in elderly people. Shimizu K, Kimura F, Akimoto T, Akama T, Tanabe K, Nishijima T, Kuno S, Kono I. Exerc Immunol Rev. 2008;14:24-37. PMID: 19203082

In vitro and in vivo immunomodulating and immunorestorative effects of Astragalus membranaceus. Cho WC, Leung KN. J Ethnopharmacol. 2007 Aug 15;113(1):132-41. Epub 2007 May 31. PMID: 17611061 doi:10.1016/j.jep.2007.05.020    

[Clinical study on effect of Astragalus in efficacy enhancing and toxicity reducing of chemotherapy in patients of malignant tumor] Duan P, Wang ZM. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2002 Jul;22(7):515-7. Chinese. PMID: 12592686

In vitro and in vivo anti-tumor effects of Astragalus membranaceus. Cho WC, Leung KN. Cancer Lett. 2007 Jul 8;252(1):43-54. Epub 2007 Jan 16. PMID: 17223259 doi:10.1016/j.canlet.2006.12.001

Chemopreventive and renal protective effects for docosahexaenoic acid (DHA): implications of CRP and lipid peroxides. Elmesery ME, Algayyar MM, Salem HA, Darweish MM, El-Mowafy AM. Cell Div. 2009 Apr 2;4(1):6. [Epub ahead of print] PMID: 19341447 doi:10.1186/1747-1028-4-6

Opposing effects of n-6 and n-3 polyunsaturated fatty acids on pancreatic cancer growth. Funahashi H, Satake M, Hasan S, Sawai H, Newman RA, Reber HA, Hines OJ, Eibl G. Pancreas. 2008 May;36(4):353-62. PMID: 18437081 doi: 10.1097/MPA.0b013e31815ccc44

Health-Information-fitness provides details for the serious, health-minded personal. We endeavor to give great details on enema use, healthy needs, colon health and common well being to help people stay more time, effective lifestyles.

omega 3 high dosage effective

Ursolic acid is a component of many herbs that seems to have a protective effect versus inflammation and its various ramifications

The active compound in marijuana, THC, can slow the growth of lung tumours and reduce the spread of the cancer in mice, a preliminary study reveals. Human lung cancer tumours grew less than half as fast in mice that received moderate doses of the compound, the researchers reveal. They hope that drugs mimicking the apparent anti-cancer effects of tetrahydrocanabinol (THC) could one day help treat patients. The team strongly discourage people from self-medicating by smoking marijuana, noting that doing so could potentially encourage tumour growth.

Researchers investigating the role of cannabis in cancer therapy reveal it has the potential to destroy leukaemia cells, in a paper published in the March 2006 edition of Letters in Drug Design & Discovery.  Led by Dr Wai Man Liu, at Barts and the London, Queen Mary's School of Medicine and Dentistry, the team has followed up on their findings of 2005 which showed that the main active ingredient in cannabis, tetrahydrocannabinol, or THC, has the potential to be used effectively against some forms of cancer.  Dr Liu has since moved to the Institute of Cancer in Sutton where he continues his work into investigating the potential therapeutic benefit of new anti-cancer agents.

A new study showing a reduction in the toxic side effects of ROS-generating chemotherapies with concurrent antioxidant supplementation will be presented at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) that takes place June 1-5 at McCormick Place in Chicago. According to the study's authors, mitigating chemotherapy toxicity by supplementing with antioxidants may improve survival rates and tumor response by helping patients complete their prescribed treatment cycles.

DCA is an odourless, colourless, inexpensive, relatively non-toxic, small molecule. And researchers at the University of Alberta believe it may soon be used as an effective treatment for many forms of cancer.

The article is written by lay individuals for information purposes only and is not to be used to diagnose or treat any disease. The document outlines therapeutic strategies which have not been clinically proven and may not be effective for lymphoma and ot

"HOUSTON - A diet that incorporates a daily dose of pistachios may help reduce the risk of lung and other cancers, according to data presented at the American Association for Cancer Research Frontiers in Cancer Prevention Research Conference, held Dec. 6-9. "It is known that vitamin E provides a degree of protection against certain forms of cancer. Higher intakes of gamma-tocopherol, which is a form of vitamin E, may reduce the risk of lung cancer," said Ladia M. Hernandez, M.S., R.D., L.D., senior research dietitian in the Department of Epidemiology at the University of Texas M. D. Anderson Cancer Center, and doctoral candidate at Texas Woman's University - Houston Center. "Pistachios are a good source of gamma-tocopherol. Eating them increases intake of gamma-tocopherol so pistachios may help to decrease lung cancer risk," she said. Pistachios are known to provide a heart-healthy benefit by producing a cholesterol-lowering effect and providing the antioxidants that are typically found in food products of plant origin. Hernandez and colleagues conducted a six-week, controlled clinical trial to evaluate if the consumption of pistachios would increase dietary intake and serum levels of gamma-tocopherol. A pistachio-rich diet could potentially help reduce the risk of other cancers from developing as well, according to Hernandez. "Because epidemiologic studies suggest gamma-tocopherol is protective against prostate cancer, pistachio intake may help," she said. "Other food sources that are a rich source of gamma-tocopherol include nuts such as peanuts, pecans, walnuts, soybean and corn oils.""

Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Michelakis ED, Webster L, Mackey JR. Br J Cancer. 2008 Oct 7;99(7):989-94. Epub 2008 Sep 2. Review. PMID: 18766181 doi:10.1038/sj.bjc.6604554 The unique metabolism of most solid tumours (aerobic glycolysis, i.e., Warburg effect) is not only the basis of diagnosing cancer with metabolic imaging but might also be associated with the resistance to apoptosis that characterises cancer. The glycolytic phenotype in cancer appears to be the common denominator of diverse molecular abnormalities in cancer and may be associated with a (potentially reversible) suppression of mitochondrial function. The generic drug dichloroacetate is an orally available small molecule that, by inhibiting the pyruvate dehydrogenase kinase, increases the flux of pyruvate into the mitochondria, promoting glucose oxidation over glycolysis. This reverses the suppressed mitochondrial apoptosis in cancer and results in suppression of tumour growth in vitro and in vivo. Here, we review the scientific and clinical rationale supporting the rapid translation of this promising metabolic modulator in early-phase cancer clinical trials More than 40 nonrandomised trials of DCA in small cohorts of patients have been reported, but the first two randomised control trials of chronic oral therapy with DCA in congenital mitochondrial diseases were reported in 2006. In the first, a blinded placebo-controlled study was performed with oral DCA administered at 25 mg kg-1 day-1 in 30 patients with MELAS syndrome (mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes) (Kaufmann et al, 2006). Most patients enrolled in the DCA arm developed symptomatic peripheral neuropathy, compared with 4 out of 15 in the placebo arm, leading to the termination of the study. Seventeen out of 19 patients had at least partial resolution of peripheral neurological symptoms by 9 months after discontinuation of DCA. This neurotoxicity res